Panacea Biotec Limited (NSE:PANACEABIO)

Panacea Biotec Statistics

Total Valuation

Panacea Biotec has a market cap or net worth of INR 22.09 billion. The enterprise value is 21.43 billion.

Market Cap	22.09B
Enterprise Value	21.43B

Important Dates

The next estimated earnings date is Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Panacea Biotec has 61.25 million shares outstanding. The number of shares has decreased by -2.84% in one year.

Current Share Class	61.25M
Shares Outstanding	61.25M
Shares Change (YoY)	-2.84%
Shares Change (QoQ)	-0.07%
Owned by Insiders (%)	68.70%
Owned by Institutions (%)	0.13%
Float	15.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.66
PB Ratio	2.69
P/TBV Ratio	2.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-295.95
EV / Sales	3.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-21.98

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.03.

Current Ratio	1.54
Quick Ratio	0.47
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.23
Interest Coverage	-15.79

Financial Efficiency

Return on equity (ROE) is -0.92% and return on invested capital (ROIC) is -8.55%.

Return on Equity (ROE)	-0.92%
Return on Assets (ROA)	-3.22%
Return on Invested Capital (ROIC)	-8.55%
Return on Capital Employed (ROCE)	-7.07%
Revenue Per Employee	2.81M
Profits Per Employee	-33,690
Employee Count	2,149
Asset Turnover	0.48
Inventory Turnover	1.38

Taxes

Income Tax	-6.69M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.22% in the last 52 weeks. The beta is 0.20, so Panacea Biotec's price volatility has been lower than the market average.

Beta (5Y)	0.20
52-Week Price Change	-19.22%
50-Day Moving Average	371.08
200-Day Moving Average	428.47
Relative Strength Index (RSI)	42.97
Average Volume (20 Days)	3,243,339

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Panacea Biotec had revenue of INR 6.04 billion and -72.40 million in losses. Loss per share was -1.18.

Revenue	6.04B
Gross Profit	3.53B
Operating Income	-642.78M
Pretax Income	-82.68M
Net Income	-72.40M
EBITDA	-327.34M
EBIT	-642.78M
Loss Per Share	-1.18

Balance Sheet

The company has 848.70 million in cash and 229.00 million in debt, with a net cash position of 619.70 million or 10.12 per share.

Cash & Cash Equivalents	848.70M
Total Debt	229.00M
Net Cash	619.70M
Net Cash Per Share	10.12
Equity (Book Value)	8.22B
Book Value Per Share	134.77
Working Capital	1.88B

Cash Flow

In the last 12 months, operating cash flow was -377.59 million and capital expenditures -597.15 million, giving a free cash flow of -974.74 million.

Operating Cash Flow	-377.59M
Capital Expenditures	-597.15M
Free Cash Flow	-974.74M
FCF Per Share	-15.91

Margins

Gross margin is 58.47%, with operating and profit margins of -10.64% and -1.20%.

Gross Margin	58.47%
Operating Margin	-10.64%
Pretax Margin	-1.37%
Profit Margin	-1.20%
EBITDA Margin	-5.42%
EBIT Margin	-10.64%
FCF Margin	n/a

Dividends & Yields

Panacea Biotec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.84%
Shareholder Yield	2.84%
Earnings Yield	-0.33%
FCF Yield	-4.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2